【摘要】 目的比较米氮平与丁螺环酮治疗惊恐障碍的疗效及安全性。方法将86例惊恐障碍患者随机分为观察组和对照组各43例,观察组予以米氮平30~60 mg/d,对照组予以丁螺环酮15~30 mg/d。两组疗程均为8周。疗效评定采用Hamilton焦虑量表(HAMA),安全性评价采用副反应量表(TESS)、实验室检查及体检。结果观察组有效率为90.7%,对照组有效率为83.7%(χ2=1.17,P>0.05);治疗1、2周末,观察组HAMA评分均低于对照组(分别为t=2.94,P<0.01;t=2.49,P<0.05),但治疗4、8周末,两组HAMA评分均无显著性差异(P>0.05)。两组不良反应程度均较轻微。结论米氮平治疗惊恐障碍起效快,疗效与丁螺环酮相仿。更多还原

【Abstract】 Objective To compare the efficacy and safety of mirtazapine and buspirone on panic disorder.Methods 86 cases with panic disorder were divided into two groups: the mirtazapine(30~60 mg/d) group and the buspirone(15~30 mg/d) group.Hamilton Anxiety Scale(HAMA) was adopted to evaluate the efficacy.Safety was evaluated with Treatment Emergent Symptom Scale(TESS),laboratorial and physical examination.Results The effective rate of mirtazapine group and buspirone group was 90.7% and 83.7% respectively 8 weeks after treatment(χ2=1.17,P>0.05).The scores of HAMA of the mirtazapine group decreased more than that of the buspirone group 1 or 2 weeks after treatment(t=2.94,P<0.01 and t=2.49,P<0.05 respectively).At the end of wk,But there was not significant difference between two groups 4 or 8 weeks after treatment(P>0.05).Some mild side-effects were observed in both groups.Conclusion Mirtazapine shows a similar effect to buspirone and takes effect earlier on panic disorder.更多还原